

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents
United States Patent and Trademark
Office
Box PCT
Washington, D.C.20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing:

31 August 2000 (31.08.00)

International application No.:

PCT/ES99/00338

Applicant's or agent's file reference:

522-99-ESPEX

International filing date:

21 October 1999 (21.10.99)

Priority date:

26 February 1999 (26.02.99)

Applicant:

BRIEVA DELGADO, Aurora et al

1. The designated Office is hereby notified of its election made:



in the demand filed with the International preliminary Examining Authority on:

16 May 2000 (16.05.00)



in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was



was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer:

J. Zahra

Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TREATY

PCT

From the INTERNATIONAL BUREAU

NOTICE INFORMING THE APPLICANT OF THE
COMMUNICATION OF THE INTERNATIONAL
APPLICATION TO THE DESIGNATED OFFICES

(PCT Rule 47.1(c), first sentence)

To:

GARCIA-CABRERIZO Y DEL SANTO,
Pedro Maria
Vitruvio, 23
E-28006 Madrid
ESPAGNE

12158

R.

0 6 SEP 2000

C.

SECRET

Date of mailing (day/month/year) 31 August 2000 (31.08.00)		IMPORTANT NOTICE	
Applicant's or agent's file reference 522-99-ESPEX			
International application No. PCT/ES99/00338	International filing date (day/month/year) 21 October 1999 (21.10.99)	Priority date (day/month/year) 26 February 1999 (26.02.99)	
Applicant INDUSTRIAL FARMACEUTICA CANTABRIA, S.A. et al			

1. Notice is hereby given that the International Bureau has communicated, as provided in Article 20, the international application to the following designated Offices on the date indicated above as the date of mailing of this Notice:
AU, KP, KR, US

In accordance with Rule 47.1(c), third sentence, those Offices will accept the present Notice as conclusive evidence that the communication of the international application has duly taken place on the date of mailing indicated above and no copy of the international application is required to be furnished by the applicant to the designated Office(s).

2. The following designated Offices have waived the requirement for such a communication at this time:

AL, AM, AP, AT, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EA, EE, EP, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, OA, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW

The communication will be made to those Offices only upon their request. Furthermore, those Offices do not require the applicant to furnish a copy of the international application (Rule 49.1(a-bis)).

3. Enclosed with this Notice is a copy of the international application as published by the International Bureau on
31 August 2000 (31.08.00) under No. WO 00/50087

REMINDER REGARDING ENTRY INTO THE NATIONAL PHASE (Article 22 or 39(1))

If the applicant wishes to proceed with the international application in the national phase, he must, within 20 months or 30 months, or later in some Offices, perform the acts referred to therein before each designated or elected Office.

For further important information on the time limits and acts to be performed for entering the national phase, see the Annex to Form PCT/18/301 (Notification of Receipt of Record Copy) and Volume II of the PCT Applicant's Guide.

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer J. Zahra
Facsimile No. (41-22) 740.14.35	Telephone No. (41-22) 338.83.38

PCT**PETITORIO**

El abajo firmante pide que la presente solicitud internacional sea tramitada de conformidad con el Tratado de Cooperación en materia de Patentes.

Para uso de la Oficina receptora únicamente

Solicitud internacional N°

Fecha de presentación internacional

Nombre de la Oficina receptora y "Solicitud internacional PCT"

Referencia al expediente del solicitante o del mandatario (si se desea)
(como máximo, 12 caracteres) 522-99-ESPEX**Recuadro N° I TITULO DE LA INVENCIÓN**

GLICOCONJUGADOS DE POLIPEPTIDOS FARMACOLOGICAMENTE ACTIVOS

R cuadro N° II SOLICITANTE

Nombre y dirección: (Apellido seguido del nombre; en el caso de una persona jurídica, la designación oficial completa. En la dirección deben figurar el código postal y el nombre del país. El país de la dirección indicada en este recuadro es el Estado de domicilio del solicitante si no se indica más abajo el Estado de domicilio.)

INDUSTRIAL FARMACEUTICA CANTABRIA, S.A.
Carretera de Cazoña-Adarzo, s/n
39011 SANTANDER
ESPAÑA

☐ Esta persona es también un inventor.

N° de teléfono

N° de facsímil

N° de teleimpresora

Estado de nacionalidad:
ESPAÑOLAEstado de domicilio:
ESPAÑA

Esta persona es solicitante para: ☐ todos los Estados designados ☒ todos los Estados designados salvo los Estados Unidos de América ☐ los Estados Unidos de América únicamente ☐ los Estados indicados en el recuadro suplementario

R cuadro N° III OTRO(S) SOLICITANTE(S) Y/O (OTRO(S)) INVENTOR(ES)

Nombre y dirección: (Apellido seguido del nombre; en el caso de una persona jurídica, la designación oficial completa. En la dirección deben figurar el código postal y el nombre del país. El país de la dirección indicada en este recuadro es el Estado de domicilio del solicitante si no se indica más abajo el Estado de domicilio.)

AURORA BRIEVA DELGADO
Josefa Valcarcel, 12 - Chalet 10
28027 MADRID

Esta persona es:

☐ solicitante únicamente

☐ solicitante e inventor

☒ inventor únicamente
(Si se marca esta casilla, no se debe rellenar lo que sigue.)
Estado de nacionalidad:
ESPAÑOLAEstado de domicilio:
ESPAÑA

Esta persona es solicitante para: ☐ todos los Estados designados ☐ todos los Estados designados salvo los Estados Unidos de América ☒ los Estados Unidos de América únicamente ☐ los Estados indicados en el recuadro suplementario

☒ Los demás solicitantes y/o (demás) inventores se indican en una hoja de continuación.

Recuadro N° IV MANDATARIO O REPRESENTANTE COMUN; O DIRECCION PARA LA CORRESPONDENCIA

La persona abajo identificada se designa/ha sido designada para actuar en nombre del/ de los solicitante(s) ante las administraciones internacionales competentes como: ☐ mandatario ☐ representante común

Nombre y dirección: (Apellido seguido del nombre; en el caso de una persona jurídica, la designación oficial completa. En la dirección deben figurar el código postal y el nombre del país.)

D. PEDRO MARIA GARCIA-CABRERIZO Y DEL SANTO
Vitruvio, 23
28006 MADRID
ESPAÑA

N° de teléfono

34 91 5 63 40 53

N° de facsímil

34 91 4 11 55 88

N° de teleimpresora

☐ Márquese esta casilla cuando no se designe/se haya designado ningún mandatario o representante común y el espacio de arriba se utilice en su lugar para indicar una dirección especial a la que deba enviarse la correspondencia.

Continuación del recuadro N° III OTROS SOLICITANTES Y/O (OTROS) INVENTORES

Si no se ha de utilizar ninguno de estos subrecuadros, esta hoja no debe ser incluida en el petitorio.

Nombre y dirección: (Apellido seguido del nombre; en el caso de una persona jurídica, la designación oficial completa. En la dirección deben figurar el código postal y el nombre del país. El país de la dirección indicada en este recuadro es el Estado de domicilio del solicitante si no se indica más abajo el Estado de domicilio.)

VICENTE GARCIA VILLARRUBIA

Cornisa, 11

Residencial La Cornisa - Bloque G 1° A

28230 LAS ROZAS (MADRID)

Esta persona es:

☐ solicitante únicamente

☐ solicitante e inventor

☒ inventor únicamente
(Si se marca esta casilla, no se debe rellenar lo que sigue.)

Estado de nacionalidad:
ESPAÑOLA

Estado de domicilio:
ESPAÑA

Esta persona es
solicitante para:

☐ todos los Estados
designados

☐ todos los Estados designados salvo los
Estados Unidos de América

☒ los Estados Unidos de
América únicamente

☐ los Estados indicados en el
recuadro suplementario

Nombre y dirección: (Apellido seguido del nombre; en el caso de una persona jurídica, la designación oficial completa. En la dirección deben figurar el código postal y el nombre del país. El país de la dirección indicada en este recuadro es el Estado de domicilio del solicitante si no se indica más abajo el Estado de domicilio.)

ANTONIO GUERRERO GOMEZ-PAMO

Plaza Reyes Magos, 13 - 9° D

28007 MADRID

Esta persona es:

☐ solicitante únicamente

☐ solicitante e inventor

☒ inventor únicamente
(Si se marca esta casilla, no se debe rellenar lo que sigue.)

Estado de nacionalidad:
ESPAÑOLA

Estado de domicilio:
ESPAÑA

Esta persona es
solicitante para:

☐ todos los Estados
designados

☐ todos los Estados designados salvo los
Estados Unidos de América

☒ los Estados Unidos de
América únicamente

☐ los Estados indicados en el
recuadro suplementario

Nombre y dirección: (Apellido seguido del nombre; en el caso de una persona jurídica, la designación oficial completa. En la dirección deben figurar el código postal y el nombre del país. El país de la dirección indicada en este recuadro es el Estado de domicilio del solicitante si no se indica más abajo el Estado de domicilio.)

JUAN PABLO PIVEL RANIERI

Antonio Arias, 12 - 6° A

28009 MADRID

Esta persona es:

☐ solicitante únicamente

☐ solicitante e inventor

☒ inventor únicamente
(Si se marca esta casilla, no se debe rellenar lo que sigue.)

Estado de nacionalidad:
ESPAÑOLA

Estado de domicilio:
ESPAÑA

Esta persona es
solicitante para:

☐ todos los Estados
designados

☐ todos los Estados designados salvo los
Estados Unidos de América

☒ los Estados Unidos de
América únicamente

☐ los Estados indicados en el
recuadro suplementario

Nombre y dirección: (Apellido seguido del nombre; en el caso de una persona jurídica, la designación oficial completa. En la dirección deben figurar el código postal y el nombre del país. El país de la dirección indicada en este recuadro es el Estado de domicilio del solicitante si no se indica más abajo el Estado de domicilio.)

GUILLERMO GIMENEZ GALLEGO

Pablo Aranda, 3

28006 MADRID

Esta persona es:

☐ solicitante únicamente

☐ solicitante e inventor

☒ inventor únicamente
(Si se marca esta casilla, no se debe rellenar lo que sigue.)

Estado de nacionalidad:
ESPAÑOLA

Estado de domicilio:
ESPAÑA

Esta persona es
solicitante para:

☐ todos los Estados
designados

☐ todos los Estados designados salvo los
Estados Unidos de América

☒ los Estados Unidos de
América únicamente

☐ los Estados indicados en el
recuadro suplementario

☒ Los demás solicitantes y/o (demás) inventores se indican en otra hoja de continuación.

Continuación d I recuadro N° III OTROS SOLICITANTES Y/O (OTROS) INVENTORES

Si no se ha de utilizar ninguno de estos subrecuadros, esta hoja no debe ser incluida en el petitorio.

Nombre y dirección: (Apellido seguido del nombre; en el caso de una persona jurídica, la designación oficial completa. En la dirección deben figurar el código postal y el nombre del país. El país de la dirección indicada en este recuadro es el Estado de domicilio del solicitante si no se indica más abajo el Estado de domicilio.)

JOSE ANTONIO MATJI TUDURI

Serramagna, 8

28043 MADRID

Esta persona es:

☐ solicitante únicamente☐ solicitante e inventor☒ inventor únicamente
(Si se marca esta casilla, no se debe rellenar lo que sigue.)Estado de nacionalidad:
ESPAÑOLAEstado de domicilio:
ESPAÑAEsta persona es solicitante para: ☐ todos los Estados designados ☐ todos los Estados designados salvo los Estados Unidos de América ☒ los Estados Unidos de América únicamente ☐ los Estados indicados en el recuadro suplementario

Nombre y dirección: (Apellido seguido del nombre; en el caso de una persona jurídica, la designación oficial completa. En la dirección deben figurar el código postal y el nombre del país. El país de la dirección indicada en este recuadro es el Estado de domicilio del solicitante si no se indica más abajo el Estado de domicilio.)

Esta persona es:

☐ solicitante únicamente☐ solicitante e inventor☐ inventor únicamente
(Si se marca esta casilla, no se debe rellenar lo que sigue.)

Estado de nacionalidad:

Estado de domicilio:

Esta persona es solicitante para: ☐ todos los Estados designados ☐ todos los Estados designados salvo los Estados Unidos de América ☐ los Estados Unidos de América únicamente ☐ los Estados indicados en el recuadro suplementario

Nombre y dirección: (Apellido seguido del nombre; en el caso de una persona jurídica, la designación oficial completa. En la dirección deben figurar el código postal y el nombre del país. El país de la dirección indicada en este recuadro es el Estado de domicilio del solicitante si no se indica más abajo el Estado de domicilio.)

Esta persona es:

☐ solicitante únicamente☐ solicitante e inventor☐ inventor únicamente
(Si se marca esta casilla, no se debe rellenar lo que sigue.)

Estado de nacionalidad:

Estado de domicilio:

Esta persona es solicitante para: ☐ todos los Estados designados ☐ todos los Estados designados salvo los Estados Unidos de América ☐ los Estados Unidos de América únicamente ☐ los Estados indicados en el recuadro suplementario

Nombre y dirección: (Apellido seguido del nombre; en el caso de una persona jurídica, la designación oficial completa. En la dirección deben figurar el código postal y el nombre del país. El país de la dirección indicada en este recuadro es el Estado de domicilio del solicitante si no se indica más abajo el Estado de domicilio.)

Esta persona es:

☐ solicitante únicamente☐ solicitante e inventor☐ inventor únicamente
(Si se marca esta casilla, no se debe rellenar lo que sigue.)

Estado de nacionalidad:

Estado de domicilio:

Esta persona es solicitante para: ☐ todos los Estados designados ☐ todos los Estados designados salvo los Estados Unidos de América ☐ los Estados Unidos de América únicamente ☐ los Estados indicados en el recuadro suplementario☐ Los demás solicitantes y/o (demás) inventores se indican en otra hoja de continuación.

R cuadro N° V DESIGNACION DE ESTADOS

A continuación se hacen las designaciones siguientes en virtud de la Regla 4.9.a) (márquense las casillas adecuadas; debe marcarse por lo menos una):

Patente regional

- ☒ **AP** Patente ARIPO : GH Ghana, GM Gambia, KE Kenya, LS Lesotho, MW Malawi, SD Sudán, SZ Swazilandia, UG Uganda, ZW Zimbabwe, y cualquier otro Estado contratante del Protocolo de Harare y del PCT
- ☒ **EA** Patente Euroasiática : AM Armenia, AZ Azerbaiyán, BY Belarús, KG Kirguistán, KZ Kazakstán, MD República de Moldova, RU Federación de Rusia, TJ Tayikistán, TM Turkmenistán, y cualquier otro Estado contratante del Convenio sobre la Patente Euroasiática y del PCT
- ☒ **EP** Patente Europea : AT Austria, BE Bélgica, CH y LI Suiza y Liechtenstein, CY Chipre, DE Alemania, DK Dinamarca, ES España, FI Finlandia, FR Francia, GB Reino Unido, GR Grecia, IE Irlanda, IT Italia, LU Luxemburgo, MC Mónaco, NL Países Bajos, PT Portugal, SE Suecia, y cualquier otro Estado contratante del Convenio sobre la Patente Europea y del PCT
- ☒ **OA** Patente OAPI : BF Burkina Faso, BJ Benin, CF República Centroafricana, CG Congo, CI Côte d'Ivoire, CM Camerún, GA Gabón, GN Guinea, GW Guinea-Bissau, ML Mali, MR Mauritania, NE Níger, SN Senegal, TD Chad, TG Togo y cualquier otro Estado que sea Estado miembro de la OAPI y que sea un Estado contratante del PCT (si se desea otra forma de protección o de tramitación, especifíquese en la línea de puntos).....

Patente nacional (si se desea otra forma de protección o de tramitación, especifíquese en la línea de puntos) :

- | | |
|--|---|
| <input checked="" type="checkbox"/> AL Albania | <input checked="" type="checkbox"/> LS Lesotho |
| <input checked="" type="checkbox"/> AM Armenia | <input checked="" type="checkbox"/> LT Lituania |
| <input checked="" type="checkbox"/> AT Austria | <input checked="" type="checkbox"/> LU Luxemburgo |
| <input checked="" type="checkbox"/> AU Australia | <input checked="" type="checkbox"/> LV Letonia |
| <input checked="" type="checkbox"/> AZ Azerbaiyán | <input checked="" type="checkbox"/> MD República de Moldova |
| <input checked="" type="checkbox"/> BA Bosnia y Herzegovina | <input checked="" type="checkbox"/> MG Madagascar |
| <input checked="" type="checkbox"/> BB Barbados | <input checked="" type="checkbox"/> MK Ex República Yugoslava de Macedonia |
| <input checked="" type="checkbox"/> BG Bulgaria | |
| <input checked="" type="checkbox"/> BR Brasil | <input checked="" type="checkbox"/> MN Mongolia |
| <input checked="" type="checkbox"/> BY Belarús | <input checked="" type="checkbox"/> MW Malawi |
| <input checked="" type="checkbox"/> CA Canadá | <input checked="" type="checkbox"/> MX México |
| <input checked="" type="checkbox"/> CH y LI Suiza y Liechtenstein | <input checked="" type="checkbox"/> NO Noruega |
| <input checked="" type="checkbox"/> CN China | <input checked="" type="checkbox"/> NZ Nueva Zelanda |
| <input checked="" type="checkbox"/> CU Cuba | <input checked="" type="checkbox"/> PL Polonia |
| <input checked="" type="checkbox"/> CZ República Checa | <input checked="" type="checkbox"/> PT Portugal |
| <input checked="" type="checkbox"/> DE Alemania | <input checked="" type="checkbox"/> RO Rumania |
| <input checked="" type="checkbox"/> DK Dinamarca | <input checked="" type="checkbox"/> RU Federación de Rusia |
| <input checked="" type="checkbox"/> EE Estonia | <input checked="" type="checkbox"/> SD Sudán |
| <input type="checkbox"/> ES España | <input checked="" type="checkbox"/> SE Suecia |
| <input checked="" type="checkbox"/> FI Finlandia | <input checked="" type="checkbox"/> SG Singapur |
| <input checked="" type="checkbox"/> GB Reino Unido | <input checked="" type="checkbox"/> SI Eslovenia |
| <input checked="" type="checkbox"/> GD Granada | <input checked="" type="checkbox"/> SK Eslovaquia |
| <input checked="" type="checkbox"/> GE Georgia | <input checked="" type="checkbox"/> SL Sierra Leona |
| <input checked="" type="checkbox"/> GH Ghana | <input checked="" type="checkbox"/> TJ Tayikistán |
| <input checked="" type="checkbox"/> GM Gambia | <input checked="" type="checkbox"/> TM Turkmenistán |
| <input checked="" type="checkbox"/> HR Croacia | <input checked="" type="checkbox"/> TR Turquía |
| <input checked="" type="checkbox"/> HU Hungría | <input checked="" type="checkbox"/> TT Trinidad y Tabago |
| <input checked="" type="checkbox"/> ID Indonesia | <input checked="" type="checkbox"/> UA Ucrania |
| <input checked="" type="checkbox"/> IL Israel | <input checked="" type="checkbox"/> UG Uganda |
| <input checked="" type="checkbox"/> IN India | <input checked="" type="checkbox"/> US Estados Unidos de América..... |
| <input checked="" type="checkbox"/> IS Islandia | |
| <input checked="" type="checkbox"/> JP Japón | <input checked="" type="checkbox"/> UZ Uzbekistán |
| <input checked="" type="checkbox"/> KE Kenya | <input checked="" type="checkbox"/> VN Viet Nam |
| <input checked="" type="checkbox"/> KG Kirguistán | <input checked="" type="checkbox"/> YU Yugoslavia |
| <input checked="" type="checkbox"/> KP República Popular Democrática de Corea | <input checked="" type="checkbox"/> ZW Zimbabwe |
| | |
| <input checked="" type="checkbox"/> KR República de Corea | |
| <input checked="" type="checkbox"/> KZ Kazakstán | |
| <input checked="" type="checkbox"/> LC Santa Lucía | <input type="checkbox"/> |
| <input checked="" type="checkbox"/> LK Sri Lanka | <input type="checkbox"/> |
| <input checked="" type="checkbox"/> LR Liberia | <input type="checkbox"/> |

Casillas reservadas para designar Estados (a los fines de una patente nacional) que han pasado a formar parte del PCT después de la publicación de la presente hoja:

Declaración sobre la designación precautoria: Además de las designaciones arriba efectuadas, el solicitante efectuará también, en virtud de la Regla 4.9.b), todas las designaciones que estén permitidas con arreglo al PCT, salvo la designación o designaciones indicadas en el recuadro suplementario como excluido del ámbito de esta declaración. El solicitante declara que esas designaciones adicionales están sujetas a confirmación y que cualquier designación que no se confirme antes de que expiren los 15 meses a partir de la fecha prioritaria se considerará retirada por el solicitante al expirar dicho plazo. (La confirmación de una designación consiste en la presentación de un aviso en el que se especifique dicha designación, así como el pago de las tasas de designación y confirmación. La confirmación deberá llegar a la Oficina receptora dentro de ese plazo de 15 meses.)

Recuadro N° VI REIVINDICACION DE PRIORIDAD

Se indican otras reivindicaciones de prioridad en el recuadro suplementario.

Fecha de presentación de la solicitud anterior (día/mes/año)	Número de la solicitud anterior	Si la solicitud anterior es:		
		solicitud nacional: país	solicitud regional:* Oficina regional	solicitud internacional: oficina receptora
Punto (1) 26 Febrero 1999	P9900408	ESPAÑA		
Punto (2)				
Punto (3)				

☒ Se ruega a la oficina receptora que prepare y transmita a la Oficina Internacional una copia certificada de la solicitud anterior/de las solicitudes anteriores (sólo si la solicitud anterior no ha sido presentada ante la oficina que a los fines de la presente solicitud internacional es la oficina receptora) identificada(s) supra como punto o puntos: 1

* Si la solicitud anterior es una solicitud ARIPO, se indicará en el recuadro suplementario por lo menos a un Estado miembro del Convenio de París para la protección de la Propiedad Industrial para el que ha sido presentada la solicitud anterior (Regla 4.10.b)II). Véase el recuadro suplementario.

R cuadro N° VII ADMINISTRACION ENCARGADA DE LA BUSQUEDA INTERNACIONAL

Elección de la Administración encargada de la búsqueda internacional (Si dos o más Administraciones encargadas de la búsqueda internacional son competentes para efectuar la búsqueda internacional, indíquese el nombre de la Administración elegida; se puede utilizar el código de dos letras): **ISA / ES**

Petición para que se utilicen los resultados de la búsqueda anterior; referencia a esa búsqueda (si una búsqueda anterior ha sido realizada por o pedida a la Administración encargada de la búsqueda internacional):

Fecha (día/mes/año): Número: País (u Oficina regional):

R cuadro N° VIII LISTA DE VERIFICACION; IDIOMA DE PRESENTACION


La presente solicitud internacional contiene el siguiente número de hojas:		La presente solicitud internacional está acompañada de los documentos que se identifican a continuación:	
petitorio :	5	1. <input checked="" type="checkbox"/> hoja de cálculo de tasas	
descripción (excepto la parte de la lista de secuencias) :	29	2. <input checked="" type="checkbox"/> poder separado firmado	
reivindicaciones :	2	3. <input type="checkbox"/> copia del poder general; número de referencia, en su caso:	
resumen :	1	4. <input type="checkbox"/> declaración que explica la ausencia de una firma	
dibujos :	1	5. <input type="checkbox"/> documento(s) de prioridad identificados en el Recuadro N° VI como punto o puntos	
parte de la lista de secuencias de la descripción :		6. <input type="checkbox"/> traducción de la solicitud internacional en (idioma):	
Número total de hojas :	38	7. <input type="checkbox"/> indicación separada relativa a microorganismos depositados u otro material biológico	
		8. <input type="checkbox"/> lista de secuencias de nucleótidos y/o aminoácidos en formato legible por ordenador	
		9. <input checked="" type="checkbox"/> otros (especifíquese): COPIA CERTIFICACION	

Figura de los dibujos que debe acompañar el resumen: 1

Idioma de presentación de la solicitud internacional: **ESPAÑOL**

Recuadro N° IX FIRMA DEL SOLICITANTE O DEL MANDATARIO

Junto a cada una de las firmas, indíquese el nombre de la persona que firma, así como su calidad (si dicha calidad no es evidente por lectura del petitorio).



PEDRO MARÍA GARCIA-CABRERIZO Y DEL SANTO

1. Fecha efectiva de recepción de la pretendida solicitud internacional:		Para la Oficina receptora únicamente		2. Dibujos:
3. Fecha efectiva de recepción, rectificada en razón de la recepción ulterior pero dentro del plazo, de documentos o de dibujos que completen la pretendida solicitud internacional:				<input type="checkbox"/> recibidos:
4. Fecha de recepción, dentro del plazo, de las correcciones solicitadas según el Artículo 11.2) del PCT:				<input type="checkbox"/> no recibidos:
5. Administración de búsqueda internacional especificada por el solicitante: ISA /		6. <input type="checkbox"/> Transmisión de la copia para la búsqueda diferida hasta que se pague la tasa de búsqueda.		

Fecha de recepción del ejemplar original por la Oficina Internacional:

Para el uso de la Oficina Internacional únicamente

PCT

HOJA DE CALCULO DE TASAS

Anexo al peticionario

Para uso de la Oficina receptora únicamente

Solicitud internacional N°

Referencia al expediente del
solicitante o del mandatario

522-99-ESPEX

Sello con la fecha de la Oficina receptora

Solicitante INDUSTRIAL FARMACEUTICA CANTABRIA, Aurora Brieva
Delgado, Vicente García Villarrubia, Antonio Guerrero
Gomez-Pamo, Juan P. Pivel Ranieri, Guillermo Gimenez
Gallego y Jose Antonio Matji Tuduri.
CALCULO DE LAS TASAS PRESCRITAS

1. TASA DE TRANSMISION 10.040.- T

2. TASA DE BUSQUEDA 157.235.- S

Búsqueda internacional a efectuar por ISA/ES
(Si dos o más Administraciones encargadas de la búsqueda internacional son componentes
respecto de la solicitud internacional, indíquese el nombre de la Administración elegida para realizar la búsqueda internacional.)
para realizar la búsqueda internacional.)

3. TASA INTERNACIONAL

Tasa de base

La solicitud internacional contiene 38 hojas.

30 primeras hojas 68.717.- b₁

8 x 1664 = 13.312.- b₂

hojas siguientes cantidad adicional

Añadir las cantidades de las casillas b₁ y b₂
e inscribir el total en la casilla B 82.029.- B

Tasas de designación

La solicitud internacional contiene 10 designaciones.

10 x 15.807.- = 158.070.- D

número de tasas de designación importe de la tasa de designación
ción pagaderas (máximo 11)

Añadir los importes inscritos de las casillas B y D
e inscribir el total en la casilla I 240.099.- I

(Los solicitantes de ciertos Estados tienen derecho a una reducción del 75% de la tasa
internacional. Si el solicitante tiene (o todos los solicitantes tienen) tal derecho,
deberá(n) inscribir en la casilla I el 25% del total de las cantidades inscritas en las
casillas B y D.)

4. TASA POR UN DOCUMENTO DE PRIORIDAD (si fuere aplicable) 4.015.- P

5. TOTAL DE LAS TASAS PAGADERAS

Añadir las cantidades inscritas en las casillas T, S, I, y P
e inscribir el resultado en la casilla TOTAL

411.389.-

TOTAL

☐ Las tasas de designación no se pagan en este momento.

FORMA DE PAGO

☐ autorización a cargar a la cuenta
de depósito (véase infra)

☐ giro bancario

☐ cupones

☐ cheque

☐ efectivo

☒ otros (especifíquese):

☐ giro postal

☐ timbres fiscales

AUTORIZACION RELATIVA A UNA CUENTA DE DEPOSITO (este modo de pago puede no estar disponible en todas las Oficinas receptoras)

La Oficina receptora/ ☐ está autorizada a cargar a mi cuenta de depósito el total de las tasas indicadas anteriormente.


☐ (esta casilla sólo puede marcarse si lo permiten las condiciones relativas a las cuentas de depósito
establecidas por la Oficina receptora) está autorizada a cargar a mi cuenta de depósito todo el importe que
falte o a abonar todo excedente en el pago del total de las tasas indicadas anteriormente.

☐ está autorizada a cargar a mi cuenta de depósito la tasa para la preparación y la transmisión del
documento de prioridad a la Oficina Internacional de la OMPI.

Número de la cuenta de depósito

Fecha (día/mes/año)

Firma



INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 522-99-ESPEX	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/ES99/00338	International filing date (day/month/year) 21/10/1999	Priority date (day/month/year) 26/02/1999
International Patent Classification (IPC) or national classification and IPC A61K47/48		
Applicant INDUSTRIAL FARMACEUTICA CANTABRIA, S.A. et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.



2. This REPORT consists of a total of 5 sheets, including this cover sheet.

- ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand 16/05/2000	Date of completion of this report 01.02.2001
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer G. Willière Telephone No. +49 89 2399 8548 

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/ES99/00338

I. Basis of the report

1. This report has been drawn on the basis of *(substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments (Rules 70.16 and 70.17).)*:

Description, pages:

1-36 as originally filed

Claims, No.:

1-6 as originally filed

Drawings, sheets:

1/1 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/ES99/00338

☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	1-6
	No:	Claims	

Inventive step (IS)	Yes:	Claims	1-6
	No:	Claims	

Industrial applicability (IA)	Yes:	Claims	1-6
	No:	Claims	

2. Citations and explanations
see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:
see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/ES99/00338

R Item V

Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Reference is made to the following documents:

D1: FR-A1-2691465

D2: US-A-5284934

2. The present application refers to glycoconjugates formed between polypeptides and specific polysaccharides fraction by non-covalent association which show immunomodulatory activity when applied via the oral route.
3. The documents D1 and D2 as cited in the International Search Report does not disclose either the specific requirements of the polypeptides, nor the association of said polypeptides which specific polysaccharides and they are silent with respect to glycoconjugates which show immunomodulatory activity when applied via the oral route.

It is thus believed that the claimed subject-matter is both novel and involves an inventive step (article 33(2) and (3) PCT).

Re Item VIII

Certain observations on the international application

The following corrections are proposed in order to clarify the wording and scope of the claims (article 6 PCT):

- a) claim 1:

The word "because" in line 5 should be replaced by "by", the word "has" in line 5 should be replaced by "having", the unit "Dka" in line 6 should be replaced by "kDa", the word "supporting" in line 6 should be replaced by "carrying" and the wording "and being whatever n-amino acids" should be replaced by "and Z_n representing n amino acids whichever they are".

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/ES99/00338

b) claim 3:

The word "because" in line 26 should be replaced by "by", the word "minor" in line 29 should be replaced by "minor subunit", the word "major" in line 32 should be replaced by "major subunit".

c) claim 4:

The word "because" in line 6 should be replaced by "by".

From the:
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

GARCIA-CABRERIZO Y DEL SANTO
Pedro Maria
Vitruvio, 23
E-28006 Madrid
ESPAGNE

PCT

WRITTEN OPINION

(PCT Rule 66)

Date of mailing
(day/month/year) 07.11.2000

Applicant's or agent's file reference
522-99-ESPEX

REPLY DUE **within 2 month(s)**
from the above date of mailing

International application No.
PCT/ES99/00338

International filing date (day/month/year)
21/10/1999

Priority date (day/month/year)
26/02/1999

International Patent Classification (IPC) or both national classification and IPC
A61K47/48

Applicant
INDUSTRIAL FARMACEUTICA CANTABRIA, S.A. et al.

1. This written opinion is the **first** drawn up by this International Preliminary Examining Authority.
2. This opinion contains indications relating to the following items:
 - I ☒ Basis of the opinion
 - II ☐ Priority
 - III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
 - IV ☐ Lack of unity of invention
 - V ☒ Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
 - VI ☐ Certain document cited
 - VII ☐ Certain defects in the international application
 - VIII ☒ Certain observations on the international application
3. The applicant is hereby **invited to reply** to this opinion.

When? See the time limit indicated above. The applicant may, before the expiration of that time limit, request this Authority to grant an extension, see Rule 66.2(d).

How? By submitting a written reply, accompanied, where appropriate, by amendments, according to Rule 66.3. For the form and the language of the amendments, see Rules 66.8 and 66.9.

Also: For an additional opportunity to submit amendments, see Rule 66.4.
For the examiner's obligation to consider amendments and/or arguments, see Rule 66.4 bis.
For an informal communication with the examiner, see Rule 66.6.

If no reply is filed, the international preliminary examination report will be established on the basis of this opinion.
4. The final date by which the international preliminary examination report must be established according to Rule 69.2 is: 26/06/2001.

Name and mailing address of the international preliminary examining authority:

European Patent Office
D-80298 Munich
Tel. +49 89 2399 - 0 Tx: 523656 epmu d
Fax: +49 89 2399 - 4465

Authorized officer / Examiner

G. Willière

Formalities officer (incl. extension of time limits)
DA ROCHA, O.
Telephone No. +49 89 2399 8101



WRITTEN OPINION

International application No. PCT/ES99/00338

I. Basis of the opinion

1. This opinion has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this opinion as "originally filed".*);

Description, pages:

1-36 as originally filed

Claims, No.:

1-6 as originally filed

Drawings, sheets:

1/1 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:

WRITTEN OPINION

International application No. PCT/ES99/00338

☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N) Claims

Inventive step (IS) Claims

Industrial applicability (IA) Claims

2. Citations and explanations
see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

se separate sheet

Re Item V

Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Reference is made to the following documents:

D1: FR-A1-2691465

D2: US-A-5284934

2. The present application refers to glycoconjugates formed between polypeptides and specific polysaccharides fraction by non-covalent association which show immunomodulatory activity when applied via the oral route.
3. The documents D1 and D2 as cited in the International Search Report does not disclose either the specific requirements of the polypeptides, nor the association of said polypeptides which specific polysaccharides and they are silent with respect to glycoconjugates which show immunomodulatory activity when applied via the oral route.

It is thus believed that the claimed subject-matter is both novel and involve an inventive step (article 33(2) and (3) PCT).

Re Item VIII

Certain observations on the international application

The following corrections are proposed in order to clarify the wording and scope of the claims (article 6 PCT):

- a) claim 1:

The word "because" in line 5 should be replaced by "by", the word "has" in line 5 should be replaced by "having", the unit "Dka" in line 6 should be replaced by "kDa", the word "supporting" in line 6 should be replaced by "carrying" and the wording "and being whatever n-amino acids" should be replaced by "and Z_n representing n amino acids whichever they are".

**WRITTEN OPINION
SEPARATE SHEET**

International application No. PCT/ES99/00338

b) claim 3:

The word "because" in line 26 should be replaced by "by", the word "minor" in line 29 should be replaced by "minor subunit", the word "major" in line 32 should be replaced by "major subunit".

c) claim 4:

The word "because" in line 6 should be replaced by "by".

The demand must be filed directly with the competent International Preliminary Examining Authority or, if two or more Authorities are competent with the one chosen by the applicant. The full name or two-letter code of that Authority may be indicated by the applicant on the line below:

IPEA/ _____

PCT

CHAPTER II

DEMAND

under Article 31 of the Patent Cooperation Treaty:

The undersigned request that the international application specified below be the subject of international preliminary examination according to the Patent Cooperation Treaty and hereby elects all eligible States (except where otherwise indicated).

For International Preliminary Examining Authority use only

Identification of IPEA

Date of receipt of DEMAND

Box No. I IDENTIFICATION OF THE INTERNATIONAL APPLICATION		Applicant's or agent's file reference 522-99-ESPEX
International application No. PCT/ES99/00338	International filing date (day/month/year) 21 Octubre 1999 (21.10.99)	(Earliest) Priority date (day/month/year) 26.02.99
Title of invention PHARMACOLOGICALLY ACTIVE POLYPEPTIDE GLYCOCONJUGATES		
Box No. II APPLICANT(S)		
Name and address: (family name followed by given name; for a legal entity, full official designation, The address must include postal code and name of country.) INDUSTRIAL FARMACEUTICA CANTABRIA, S.A. Carretera de Cazoña-Adarzo, s/n 39011 SANTANDER SPAIN		Telephone No.: Facsimile No.: Teleprinter No.:
State (that is, country) of nationality SPANISH	State (that is, country) of residence: SPAIN	
Name and address: (family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.) AURORA BRIEVA DELGADO Josefa Valcarcel, 12 - Chalet 10 28027 MADRID SPAIN		
State (that is, country) of nationality: SPANISH	State (that is, country) of residence: SPAIN	
Name and address: (family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.) VICENTE GARCIA VILLARRUBIA Cornisa, 11 Residencial La Cornisa - Bloque G 1° A 28230 LAS ROZAS MADRID SPAIN		
State (that is, country) of nationality: SPANISH	State (that is, country) of residence: SPAIN	
<input checked="" type="checkbox"/> Further applicants are indicated on a continuation sheet.		

Continuation of Box No. II APPLICANT(S)

If none of the following sub-boxes is used, this sheet should not be included in the demand.

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)*

ANTONIO GUERRERO GOMEZ-PAMO
Plaza Reyes Magos, 13 - 9° D
28007 MADRID
SPAIN

State (that is, country) of nationality:
SPANISH

State (that is, country) of residence:
SPAIN

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)*

JUAN PABLO PIVEL RANIERI
Antonio Arias, 12 - 6° A
28009 MADRID
SPAIN°

State (that is, country) of nationality:
SPANISH

State (that is, country) of residence:
SPAIN

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)*

GUILLERMO GIMENEZ GALLEGO
Pablo Aranda, 3
28006 MADRID
SPAIN

State (that is, country) of nationality:
SPANISH

State (that is, country) of residence:
SPAIN

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)*

JOSE ANTONIO MATJI TUDURI
Serramagna, 8
28043 MADRID
SPAIN

State (that is, country) of nationality:
SPANISH

State (that is, country) of residence:
SPAIN

☐ Further applicants are indicated on another continuation sheet.

Box No. III AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE

The following person is ☒ agent ☐ common representative
 and ☒ has been appointed earlier and represents the applicant(s) also for international preliminary examination.
☐ is hereby appointed and any earlier appointment of (an) agent(s)/common representative is hereby revoked.
☐ is hereby appointed, specifically for the procedure before the International Preliminary Examining Authority, in addition to the agent(s)/common representative appointed earlier.

Name and address: *(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)*

GARCIA-CABRERIZO Y DEL SANTO, PEDRO MARIA
 Vitruvio, 23
 28006 MADRID
 SPAIN

Telephone No.:

34 91 5 63 40 53

Facsimile No.

34 91 4 11 55 88

Teleprinter No.:

☐ Address for correspondence: Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.

Box No. IV BASIS FOR INTERNATIONAL PRELIMINARY EXAMINATION**Statement concerning amendments:***

1. The applicant wishes the international preliminary examination to start on the basis of:

☒ the international application as originally filed

the description ☒ as originally filed
☐ as amended under Article 34

the claims ☒ as originally filed
☐ as amended under Article 19 (together with any accompanying statement)
☐ as amended under Article 34

the drawings ☒ as originally filed
☐ as amended under Article 34

2. ☐ The applicant wishes any amendment to the claims under Article 19 to be considered as reversed.

3. ☐ The applicant wishes the start of the international preliminary examination to be postponed until expiration of 20 months from the priority date unless the International Preliminary Examining Authority receives a copy of any amendments made under Article 19 or a notice from the applicant that he does not wish to make such amendments (Rule 69.1(d)). (This check-box may be marked only where the time limit under Article 19 has not yet expired.)

* Where no check-box is marked, international preliminary examination will start on the basis of the international application as originally filed or, where a copy of amendments to the claims under Article 19 and/or amendments of the international application under Article 34 are received by the International Preliminary Examining Authority before it has begun to draw up a written opinion or the international preliminary examination report, as so amended.

Language for the purposes of international preliminary examination:

- ☐ which is the language in which the international application was filed.
☐ which is the language of a translation furnished for the purposes of international search.
☐ which is the language of publication of the international application.
☒ which is the language of the translation (to be) furnished for the purposes of international preliminary examination.

Box No. V ELECTION OF STATES

The applicant hereby elects all eligible States (that is, all States which have been designated and which are bound by Chapter II of the PCT)

excluding the following States which the applicant wishes not to elect:

Box No. VI CHECK LIST

The demand is accompanied by the following elements, in the language referred to in Box No. IV, for the purposes of international preliminary examination:

- | | | |
|--|---|-----------|
| 1. translation of international application | : | 39 sheets |
| 2. amendments under Article 34 | : | sheets |
| 3. copy (or, where required, translation) of amendments under Article 19 | : | sheets |
| 4. copy (or, where required, translation) of statement under Article 19 | : | sheets |
| 5. letter | : | sheets |
| 6. other (specify): drawings | : | 1 sheets |

For International Preliminary
Examining Authority use only

received	not received
----------	--------------

<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>

The demand is also accompanied by the item(s) marked below:

- | | |
|--|---|
| 1. <input checked="" type="checkbox"/> fee calculation sheet | 4. <input type="checkbox"/> statement explaining lack of signature |
| 2. <input type="checkbox"/> separate signed power of attorney | 5. <input type="checkbox"/> nucleotide and or amino acid sequence listing in computer readable form |
| 3. <input type="checkbox"/> copy of general power of attorney; reference number, if any: | 6. <input type="checkbox"/> other (specify): |

Box No. VII SIGNATURE OF APPLICANT, AGENT OR COMMON REPRESENTATIVE

Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the demand).



PEDRO MARIA GARCIA-CABRERIZO Y DEL SANTO

For International Preliminary Examining Authority use only

1. Date of actual receipt of DEMAND:

2. Adjusted date of receipt of demand due to CORRECTIONS under Rule 60.1(b):

- | | |
|--|---|
| 3. <input type="checkbox"/> The date of receipt of the demand is AFTER the expiration of 19 months from the priority date and item 4 or 5, below, does not apply. | <input type="checkbox"/> The applicant has been informed accordingly. |
| 4. <input type="checkbox"/> The date of receipt of the demand is WITHIN the period of 19 months from the priority date as extended by virtue of Rule 80.5. | |
| 5. <input type="checkbox"/> Although the date of receipt of the demand is after the expiration of 19 months from the priority date, delay in arrival is EXCUSED pursuant to Rule 82. | |

For International Bureau use only

Demand received from IPEA on:

PCT

FEE CALCULATION SHEET

Annex to the Demand for international preliminary examination

<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">International application No.</td> <td style="width: 50%;">PCT/ES99/00338</td> </tr> <tr> <td>Applicant's or agent's file reference</td> <td>522-99-ESPEX</td> </tr> </table>	International application No.	PCT/ES99/00338	Applicant's or agent's file reference	522-99-ESPEX	<div style="border: 1px solid black; padding: 5px;"> For international Preliminary Examining Authority use only </div> <div style="border: 1px solid black; height: 100px; margin-top: 10px;"> Date stamp of the IPEA </div>
International application No.	PCT/ES99/00338				
Applicant's or agent's file reference	522-99-ESPEX				
Applicant INDUSTRIAL FARMACEUTICA CANTABRIA, S.A. - AURORA BRIEVA - VICENTE GARCIA - ANTONIO GUERRERO - JUAN PABLO PIVEL - GUILLERMO GIMENEZ and JOSE ANTONIO MATJI					
Calculation of prescribed fees					
1. Preliminary examination fee	255.070.- P				
2. Handling fee (<i>Applicants from certain States are entitled to a reduction of 75% of the handling fee. Where the applicant is (or all applicants are) so entitled, the amount to be entered at H is 25% of the handling fee.</i>)	24.459.- H				
3. Total of prescribed fees Add the amounts entered at P and H and enter total in the TOTAL box	<div style="border: 1px solid black; padding: 2px;">279.529.-</div> <div style="border: 1px solid black; padding: 2px; margin-top: 2px;">TOTAL</div>				
Mode of Payment					
<input type="checkbox"/> authorization to charge deposit account with the IPEA (see below)	<input type="checkbox"/> cash				
<input type="checkbox"/> cheque	<input type="checkbox"/> revenue stamps				
<input type="checkbox"/> postal money order	<input type="checkbox"/> coupons				
<input checked="" type="checkbox"/> bank draft	<input type="checkbox"/> other (specify):				
Deposit Account Authorization (<i>this mode of payment may not be available at all IPEAs</i>)					
The IPEA/ _____ <input type="checkbox"/> is hereby authorized to charge the total fees indicated above to my deposit account.					
<input type="checkbox"/> (<i>this check-box may be marked only if the conditions for deposit accounts of the IPEA so permits hereby authorized to charge any deficiency or credit any overpayment in the total fees indicated above to my deposit account.</i>)					
Deposit Account Number _____	Date (day/month/year) _____				
Signature _____					

INTERNATIONAL SEARCH REPORT

International application No.
PCT/ES 99/00338A. CLASSIFICATION OF SUBJECT MATTER⁶:

IPC7: A61K 47/48, C07K 14/415

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7:A61K. C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EPODOC, PAJ, CA, BIOSIS, WPIL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	FR 2691465 A1 (P. FABRE MEDICAMENT) 26 November 1993 (26.11.93) The whole document	1-6
A	US 5284934 A (H.J.Allen, Jr.) 08 February 1994 (08.02.94) the whole document	1-6



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search
07 February 2000 (07.02.00)Date of mailing of the international search report
17 February 2000 (17.02.00)Name and mailing address of the ISA /
Facsimile No. S.P.T.OAuthorized officer
Telephone No.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/ ES 99/00338

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR 2691465 A1	26.11.1993	NONE	
US 5284934 A	08.02.1994	NONE	